• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

获得性难治性血小板减少性紫癜患者动态心脏生物标志物的预后价值:中国人群的回顾性研究。

Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.

机构信息

Hematological Intensive Care Unit,Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.

Department of Cardiology, The First Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

J Clin Lab Anal. 2022 Jul;36(7):e24547. doi: 10.1002/jcla.24547. Epub 2022 Jun 11.

DOI:10.1002/jcla.24547
PMID:35689538
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9280007/
Abstract

INTRODUCTION

Thrombotic thrombocytopenic purpura (TTP) is becoming a curable disease with the introduction of therapeutic plasma exchange (TPE). However, cardiovascular complications remain essential causes of mortality in patients with refractory TTP, while the association of cardiac biomarkers with the prognosis of TTP warrants further investigation.

METHODS

Patients admitted to the First Affiliated Hospital of Soochow University for refractory TTP from 2013 through 2020 were included in this retrospective study. Clinical characteristics were collected from electronic health records. Biomarker levels on admission and post TPE were recorded. Logistic regression was adopted to identify risk factors for mortality.

RESULTS

A total of 78 patients with refractory TTP were included in this study. Twenty-one patients died during hospitalization, with a mortality rate of 26.9%. High-sensitivity cardiac troponin T (hs-cTnT), N-terminal probrain natriuretic peptide (NT-proBNP), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ratios (AAR) were increased in deceased patients compared with the survival group. Multivariate analysis showed that AAR after TPE was associated with overall mortality (OR: 4.45, 95% CI 1.09-18.19). The areas under the receiver operator characteristic curve (AUC) of AAR, hs-cTnT, and NT-proBNP for the association with mortality were 0.814, 0.840, and 0.829, respectively.

CONCLUSION

Higher post-TPE cardiac biomarker levels are associated with increased in-hospital mortality in patients with refractory TTP.

摘要

简介

随着治疗性血浆置换(TPE)的引入,血栓性血小板减少性紫癜(TTP)已成为一种可治愈的疾病。然而,心血管并发症仍然是难治性 TTP 患者死亡的主要原因,而心脏生物标志物与 TTP 预后的相关性仍需进一步研究。

方法

本回顾性研究纳入了 2013 年至 2020 年期间苏州大学第一附属医院收治的难治性 TTP 患者。从电子病历中收集临床特征。记录入院时和 TPE 后的生物标志物水平。采用逻辑回归识别死亡的危险因素。

结果

本研究共纳入 78 例难治性 TTP 患者。21 例患者在住院期间死亡,死亡率为 26.9%。死亡患者的高敏肌钙蛋白 T(hs-cTnT)、N 末端脑利钠肽前体(NT-proBNP)和天冬氨酸氨基转移酶(AST)与丙氨酸氨基转移酶(ALT)比值(AAR)均高于存活组。多因素分析显示,TPE 后 AAR 与总死亡率相关(OR:4.45,95%CI 1.09-18.19)。AAR、hs-cTnT 和 NT-proBNP 与死亡率相关的受试者工作特征曲线(ROC)下面积(AUC)分别为 0.814、0.840 和 0.829。

结论

难治性 TTP 患者 TPE 后心脏生物标志物水平升高与住院期间死亡率增加相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0d3/9280007/d8d09175ba97/JCLA-36-e24547-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0d3/9280007/d8d09175ba97/JCLA-36-e24547-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d0d3/9280007/d8d09175ba97/JCLA-36-e24547-g001.jpg

相似文献

1
Prognostic value of dynamic cardiac biomarkers in patients with acquired refractory thrombocytopenic purpura: A retrospective study in Chinese population.获得性难治性血小板减少性紫癜患者动态心脏生物标志物的预后价值:中国人群的回顾性研究。
J Clin Lab Anal. 2022 Jul;36(7):e24547. doi: 10.1002/jcla.24547. Epub 2022 Jun 11.
2
Therapeutical plasma exchange for thrombotic thrombocytopenic purpura in the emergency department: A single center experience.急诊治疗血栓性血小板减少性紫癜的治疗性血浆置换:单中心经验。
Am J Emerg Med. 2021 Aug;46:556-559. doi: 10.1016/j.ajem.2020.11.019. Epub 2020 Nov 12.
3
High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide in acute heart failure: Data from the ACE 2 study.急性心力衰竭中心脏肌钙蛋白 T 高敏和 N 末端 pro-B 型利钠肽:来自 ACE 2 研究的数据。
Clin Biochem. 2021 Feb;88:30-36. doi: 10.1016/j.clinbiochem.2020.11.009. Epub 2020 Nov 25.
4
Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements.联合检测高敏肌钙蛋白 T 和 N 末端脑利钠肽前体对老年心力衰竭症状患者的预后评估。
Clin Chem. 2010 Nov;56(11):1718-24. doi: 10.1373/clinchem.2009.141341. Epub 2010 Sep 15.
5
Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.联合使用高敏心肌肌钙蛋白 T 和 N 末端脑利钠肽前体可改善慢性心力衰竭患者的预后,优于传统的死亡风险因素。
Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.
6
Blood-Based Cardiac Biomarkers and the Risk of Cognitive Decline, Cerebrovascular Disease, and Clinical Events.基于血液的心脏生物标志物与认知功能下降、脑血管疾病及临床事件的风险
Stroke. 2021 Jul;52(7):2275-2283. doi: 10.1161/STROKEAHA.120.032571. Epub 2021 May 11.
7
Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study.治疗性血浆置换治疗血栓性血小板减少性紫癜:一项回顾性多中心研究。
Transfus Apher Sci. 2007 Feb;36(1):57-67. doi: 10.1016/j.transci.2006.05.014. Epub 2007 Jan 19.
8
Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a retrospective evaluation.比较淋巴血浆置换与治疗性血浆置换治疗血栓性血小板减少性紫癜的疗效:回顾性评估。
Hematology. 2022 Dec;27(1):167-172. doi: 10.1080/16078454.2021.2015842.
9
Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study.血栓性血小板减少性紫癜患者的治疗性血浆置换:一项回顾性多中心研究。
Transfus Apher Sci. 2013 Jun;48(3):353-8. doi: 10.1016/j.transci.2013.04.016. Epub 2013 Apr 18.
10
Serum D-dimer as a potential new biomarker for prognosis in patients with thrombotic thrombocytopenic purpura.血清D-二聚体作为血栓性血小板减少性紫癜患者预后的潜在新生物标志物。
Medicine (Baltimore). 2020 Mar;99(13):e19563. doi: 10.1097/MD.0000000000019563.

引用本文的文献

1
[Thrombopenia and hemolytic anemia in acute and emergency medicine : Detailed view at thrombotic microangiopathies].[急性和急诊医学中的血小板减少症与溶血性贫血:血栓性微血管病的详细视角]
Inn Med (Heidelb). 2025 Jan;66(1):64-81. doi: 10.1007/s00108-024-01835-8. Epub 2025 Jan 22.

本文引用的文献

1
Advances in the management of TTP.血栓性血小板减少性紫癜治疗的进展。
Blood Rev. 2022 Sep;55:100945. doi: 10.1016/j.blre.2022.100945. Epub 2022 Feb 17.
2
Association Between Systemic Inflammation and Individual Symptoms of Depression: A Pooled Analysis of 15 Population-Based Cohort Studies.系统性炎症与抑郁个体症状之间的关联:15 项基于人群的队列研究的汇总分析。
Am J Psychiatry. 2021 Dec;178(12):1107-1118. doi: 10.1176/appi.ajp.2021.20121776. Epub 2021 Oct 14.
3
Serum level of high sensitive C-reactive protein and IL - 6 markers in patients with treatment-resistant schizophrenia in Ethiopia: a comparative study.
血清高敏 C 反应蛋白和白细胞介素-6 标志物在埃塞俄比亚治疗抵抗性精神分裂症患者中的水平:一项比较研究。
BMC Psychiatry. 2021 Aug 31;21(1):428. doi: 10.1186/s12888-021-03443-4.
4
TTP: the evolution of clinical practice.血栓性血小板减少性紫癜:临床实践的演变
Blood. 2021 Feb 11;137(6):719-720. doi: 10.1182/blood.2020009654.
5
Serum Mitochondrial Quality Control Related Biomarker Levels are Associated with Organ Dysfunction in Septic Patients.血清线粒体质量控制相关生物标志物水平与脓毒症患者的器官功能障碍有关。
Shock. 2021 Sep 1;56(3):412-418. doi: 10.1097/SHK.0000000000001737.
6
Cardiovascular Complications and Their Association With Mortality in Patients With Thrombotic Thrombocytopenic Purpura.血栓性血小板减少性紫癜患者的心血管并发症及其与死亡率的关系。
Am J Med. 2021 Feb;134(2):e89-e97. doi: 10.1016/j.amjmed.2020.06.020. Epub 2020 Jul 18.
7
Association between Alanine Aminotransferase/Aspartate Aminotransferase Ratio (AST/ALT Ratio) and Coronary Artery Injury in Children with Kawasaki Disease.川崎病患儿丙氨酸氨基转移酶/天冬氨酸氨基转移酶比值(AST/ALT比值)与冠状动脉损伤的关系
Cardiol Res Pract. 2020 Mar 23;2020:8743548. doi: 10.1155/2020/8743548. eCollection 2020.
8
AST/ALT ratio predicts the functional severity of chronic heart failure with reduced left ventricular ejection fraction.谷草转氨酶/谷丙转氨酶比值可预测左心室射血分数降低的慢性心力衰竭的功能严重程度。
BMC Res Notes. 2020 Mar 24;13(1):178. doi: 10.1186/s13104-020-05031-3.
9
Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.关于血栓性血小板减少性紫癜患者 ICU 管理的专家声明。
Intensive Care Med. 2019 Nov;45(11):1518-1539. doi: 10.1007/s00134-019-05736-5. Epub 2019 Oct 7.
10
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.卡普拉珠单抗治疗获得性血栓性血小板减少性紫癜。
N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.